News | November 15, 2023
IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Lack of technology transfer stands out as a formidable barrier
Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Subscribe To Our Newsletter & Stay Updated
